Irritable bowel syndrome
Conditions
Interventions
Trimebutine treatment group:Trimebutine maleate tablets were given orally for 100 mg three times a day
Trimebutine combined with Mesengan treatment group:Trimebutine Maleate Tablets 3 times a day (30 minutes before meals)+Mechanoan 500 mg orally 3 times a day
Sponsors
Hospital of Chengdu Office of the People's Government of Tibet Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the experimental group: (1) Compliance with IBS diagnostic criteria; (2) Aged 18-70 years, Tibetan, male and female; (3) The general situation is good; (4) Informed consent, voluntary participation in research. Inclusion criteria for the control group were as follows: (1) Compliance with IBS diagnostic criteria; (2) Aged 18-70 years, Han nationality, male and female; (3) The general situation is good; (4) Informed consent, voluntary participation in research.
Exclusion criteria
Exclusion criteria: Exclusion criteria of experimental group: (1) There are organic lesions of digestive tract or systemic diseases affecting digestive tract motility after clinical observation and instrument examination. (2) Severe primary diseases such as heart, brain, liver, kidney, endocrine and blood system; (3) Compliance is poor (such as not being able to visit regularly, not using drugs on time, not using drugs according to the standard, etc.) or other experimental studies at the same time; (4) In the past two weeks, we have taken the drugs that affect the test, such as antibiotics, acid suppressants, gastrointestinal stimulants, antidepressants, opioids, etc. Those who are allergic to drugs or allergic constitutions used in some research institutes; (5) Pregnancies, physical and mental disorders, lactose intolerance, lactation women, etc. (6) Those who have been in the Mainland for more than two weeks and whose dietary habits have changed a lot. (7) Incomplete clinical data. (8) Those who are contraindicated with trimebutine or mechangan. Exclusion criteria of control group: (1) There are organic lesions of digestive tract or systemic diseases affecting digestive tract motility after clinical observation and instrument examination. (2) Severe primary diseases such as heart, brain, liver, kidney, endocrine and blood system; (3) Compliance is poor (such as not being able to visit regularly, not using drugs on time, not using drugs according to the standard, etc.) or other experimental studies at the same time; (4) In the past two weeks, we have taken the drugs that affect the test, such as antibiotics, acid inhibitors, gastrointestinal stimulants, antidepressants, opioids, etc. Those who have allergic allergies or allergic constitutions used in some research institutes. (5) Pregnancies, physical and mental disorders, lactose intolerance, lactation women, etc. (6) Incomplete clinical data. (7) those who are contraindicated with trimebutine or mechangan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stool flora; | — |
Countries
China
Contacts
Public ContactHuan Hui
Hospital of Chengdu Office of the People's Government of Tibet Autonomous Region
Outcome results
None listed